Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon

Author(s):

Panelists discuss how emerging targeted and biomarker-directed therapies are poised to transform the treatment landscape for both limited-stage and extensive-stage small cell lung cancer, highlighting the potential for improved patient outcomes through personalized approaches.

EP: 1.Current Landscape of First-Line Treatment for Limited-Stage SCLC: Diagnostic Workup & Multidisciplinary Approaches

EP: 2.Surgical and Radiotherapy Choices in Limited-Stage SCLC

EP: 3.Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

EP: 4.Immunotherapy in Limited-Stage SCLC

EP: 5.Defining Platinum Sensitivity in SCLC

EP: 6.Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

EP: 7.Adverse Event Management: CRS and ICANS with Tarlatamab

EP: 8.Tarlatamab in Combination Therapy: Future Potential for SCLC

EP: 9.Ifinatamab Deruxtecan and B7-H3 in SCLC

EP: 10.Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC

EP: 11.Insights from ARTEMIS-001

Now Viewing

EP: 12.Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon

Video content above is prompted by the following:

What lies on the horizon for early-phase studies of future, targeted, and/or biomarker-directed therapies for limited-stage and extensive-stage small cell lung cancer?